Literature DB >> 28599373

The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology and clinical implications.

Aldo Clerico1, Martina Zaninotto1, Andrea Ripoli1, Silvia Masotti1, Concetta Prontera1, Claudio Passino1, Mario Plebani1.   

Abstract

According to recent international guidelines, including the 2012 Third Universal Definiton of Myocardial Infarction by the Joint ESC/ACCF/AHA/WHF Task Force, an increase in cardiac troponin (cTn) levels over the 99th percentile upper reference limit (99th URL) should be considered clinically relevant, this cut-off being measured with an imprecision ≤10 CV%. In theory 99th URL values strongly depend not only on demographic and physiological variables (i.e. criteria for considering the reference population "healthy"), but also on the analytical performance of cTn methods and mathematical algorithms used for the calculation. The aim of the present article was therefore to review the methodological and pathophysiological factors affecting the evaluation and calculation of the 99th URL for cTn assay. The critical analysis made showed that no uniform procedure is followed, and nor have experts or regulatory bodies provided uniform guidelines for researchers or cTn assays manufacturers as an aid in "their quest to define normality". In particular, little attention has been paid to the way in which a healthy reference population is to be selected, or the criteria for calculating the 99th URL value for cTn assays, thus highlighting the need for international recommendations not only for demographic and physiological variables criteria for defining a healthy reference population, but also for calculating mathematical algorithms for establishing/calculating clinical decision values. An expert consensus group, comprising laboratory and clinical scientists, biomedical statisticians, industrial and regulatory representatives, should be responsible for drawing up these guidelines.

Entities:  

Keywords:  cardiac troponins; gender specific decision values; highly sensitive immunoassay; quality specification; reference population

Mesh:

Substances:

Year:  2017        PMID: 28599373     DOI: 10.1515/cclm-2016-0933

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  11 in total

1.  Determination of high sensitive cardiac troponin I 99th percentile upper reference limits in a healthy Pakistani population.

Authors:  Kulsoom Bahadur; Aamir Ijaz; Momin Salahuddin; Aftab Alam
Journal:  Pak J Med Sci       Date:  2020 Sep-Oct       Impact factor: 1.088

Review 2.  Natriuretic Peptides and Troponins to Predict Cardiovascular Events in Patients Undergoing Major Non-Cardiac Surgery.

Authors:  Marco Alfonso Perrone; Alberto Aimo; Sergio Bernardini; Aldo Clerico
Journal:  Int J Environ Res Public Health       Date:  2022-04-24       Impact factor: 4.614

Review 3.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

4.  Frequency histograms of three high-sensitivity cardiac troponin assays in a reference population.

Authors:  Hanwool Cho; Hyunjung Kim; Jehoon Lee; Soo-Young Kim; Hae Kyung Lee; Hi Jeong Kwon; Yeongsic Kim
Journal:  J Clin Lab Anal       Date:  2022-04-20       Impact factor: 3.124

5.  ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.

Authors:  Nadia Aspromonte; Michele Massimo Gulizia; Aldo Clerico; Giuseppe Di Tano; Michele Emdin; Mauro Feola; Massimo Iacoviello; Roberto Latini; Andrea Mortara; Roberto Valle; Gianfranco Misuraca; Claudio Passino; Serge Masson; Alberto Aimo; Marcello Ciaccio; Marco Migliardi
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 6.  Sex-Specific Cut-Offs for High-Sensitivity Cardiac Troponin: Is Less More?

Authors:  Giulio Francesco Romiti; Roberto Cangemi; Filippo Toriello; Eleonora Ruscio; Susanna Sciomer; Federica Moscucci; Marianna Vincenti; Clara Crescioli; Marco Proietti; Stefania Basili; Valeria Raparelli
Journal:  Cardiovasc Ther       Date:  2019-02-05       Impact factor: 3.023

7.  Effect of Outlier Elimination on the 99th Percentile Upper Reference Limits of High-Sensitivity Cardiac Troponin I Assays Based on a Strictly Selected Healthy Reference Population.

Authors:  Sunyoung Ahn; Hyun-Ki Kim; Woochang Lee; Sail Chun; Won-Ki Min
Journal:  Ann Lab Med       Date:  2022-05-01       Impact factor: 3.464

8.  High-Sensitivitycardiac Troponinsin Cardio-Healthy Subjects: A Cardiovascular Magnetic Resonance Imaging Study.

Authors:  Tar-Choon Aw; Wei-Ting Huang; Thu-Thao Le; Chee-Jian Pua; Briana Ang; Soon-Kieng Phua; Khung-Keong Yeo; Stuart A Cook; Calvin W L Chin
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

9.  The comparison of analytical performances of Mindray CL-1000i and Beckman Coulter Access II Troponin I methods in the light of recent guidelines and the quality requirements.

Authors:  Giray Bozkaya; Ali Rıza Sisman
Journal:  Ann Transl Med       Date:  2020-10

10.  Disagreement between Cardiac Troponin Tests Yielding a Higher Incidence of Myocardial Injury in the Emergency Setting.

Authors:  Peter A Kavsak; Shawn E Mondoux; Janet Martin; Mark K Hewitt; Lorna Clark; Nadia Caruso; Ching-Tong Mark; V Tony Chetty; Craig Ainsworth; Andrew Worster
Journal:  J Cardiovasc Dev Dis       Date:  2021-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.